Business
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
- Combination therapy to be evaluated in a Phase 3 trial in patients with locoregionally advanced, high-risk, HPV16/18-positive head and neck cancer PLYMOUTH
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"- Combination therapy to be evaluated in a Phase 3 trial in patients with locoregionally advanced, high-risk, HPV16/18-positive head and neck cancer\nPLYMOUTH MEETING, Pa. and REDWOOD CITY, Calif., Jan. 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) to evaluate the combination of INO-3112 and LOQTORZI™ (toripalimab-tpzi) as a potential treatment for patients with locoregionally advanced, high-risk, HPV16/18 positive oropharyngeal squamous cell carcinoma (OPSCC), a type of head and neck cancer commonly known as throat cancer.\n\n \n \n \n \n \n \n\n \nUnder the terms of the supply agreement, Coherus will provide LOQTORZI™ (toripalimab-tpzi), for a Phase 3 clinical trial to be conducted by INOVIO, pending alignment with the U.S. Food and Drug Administration (FDA) on study design. LOQTORZI™ is a PD-1 inhibitor recently approved by the FDA for the treatment of recurrent locally advanced/metastatic nasopharyngeal carcinoma (R/P NPC).\n\"Existing trial data highlights the strong rationale for and potential benefit of combining INO-3112 with a PD-1 inhibitor to generate tumor-specific T cells in HPV-related head and neck cancer,\" said Dr. Glenn Hanna, Director of the Center for Cancer Therapeutic Innovation (early drug development program) at Dana Farber Cancer Institute, Assistant Professor of Medicine at Harvard Medical School and principal investigator for the planned trial. \"I look forward to advancing this research for patients by harnessing their immune system to fight against this life-altering, virally mediated cancer.\"\n\"We are very pleased to be collaborating with Coherus on this novel combination therapy and are excited about the opportunity to build on encouraging data from our previous trials involving INO-3112 in HPV-related head and neck cancer,\" said INOVIO's President and Chief Executive Officer, Dr. Jacqueline Shea. \"There is unique potential in combining our DNA medicines platform, which a growing body of research indicates is adept at fighting HPV-related diseases, with a proven PD-1 inhibitor to improve clinical outcomes for...